


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) Compounds of the formula I



in which

- $\text{R}^1, \text{R}^2$  are each, independently of one another, H, =O, Hal, A, ethynyl,  $\text{OR}^3$ ,  $\text{N}(\text{R}^3)_2$ ,  $\text{NO}_2$ , CN,  $\text{N}_3$ ,  $\text{COOR}^3$ ,  $\text{CON}(\text{R}^3)_2$ ,  $-\text{[C(R}^4)_2\text{]}_n\text{-Ar}$ ,  $-\text{[C(R}^4)_2\text{]}_n\text{-Het}$ ,  $-\text{[C(R}^4)_2\text{]}_n\text{-cycloalkyl}$ ,  $-\text{OCOR}^3$ ,  $-\text{OCON}(\text{R}^3)_2$ ,  $\text{NR}^3\text{COA}$  or  $\text{NR}^3\text{SO}_2\text{A}$ ,
- $\text{R}^1$  and  $\text{R}^2$  together are alternatively a bicyclically or spirocyclically bonded 3- to 7-membered carbocyclic or heterocyclic ring having from 0 to 3 N, O and/or S atoms,
- $\text{R}^3$  is H, A,  $\text{H-C}\equiv\text{C-CH}_2\text{-}$ ,  $\text{CH}_3\text{-C}\equiv\text{C-CH}_2\text{-}$ ,  $-\text{CH}_2\text{-CH(OH)-CH}_2\text{OH}$ ,  $-\text{CH}_2\text{-CH(OH)-CH}_2\text{NH}_2$ ,  $-\text{CH}_2\text{-CH(OH)-CH}_2\text{Het}'$ ,  $-\text{[C(R}^4)_2\text{]}_n\text{-Ar}'$ ,  $-\text{[C(R}^4)_2\text{]}_n\text{-Het}'$ ,  $-\text{[C(R}^4)_2\text{]}_n\text{-cycloalkyl}$ ,  $-\text{[C(R}^4)_2\text{]}_n\text{-COOA}$  or  $-\text{[C(R}^4)_2\text{]}_n\text{N(R}^4)_2$ ,
- $\text{R}^4$  is H or A,
- W is N,  $\text{CR}^3$  or an  $\text{sp}^2$ -hybridised carbon atom,
- E together with W is a 3- to 7-membered saturated carbocyclic or heterocyclic ring having from 0 to 3 N, from 0 to 2 O and/or from 0 to 2 S atoms,
- which may contain a double bond,
- D is a monocyclic or bicyclic, aromatic carbocyclic or heterocyclic ring having from 0 to 4 N, O and/or S atoms which is unsubstituted or monosubstituted or polysubstituted by Hal, A,  $\text{OR}^3$ ,  $\text{N(R}^3)_2$ ,  $\text{NO}_2$ , CN,  $\text{COOR}^3$  or  $\text{CON(R}^3)_2$ ,

- G is  $-\text{C}(\text{R}^4)_2\text{]}_n-$ ,  $-\text{C}(\text{R}^4)_2\text{]}_n\text{NR}^3-$ ,  $-\text{C}(\text{R}^4)_2\text{]}_n\text{O}-$ ,  $-\text{C}(\text{R}^4)_2\text{]}_n\text{S}-$  or  $-\text{C}(\text{R}^4)=\text{C}(\text{R}^4)\text{]}_n-$ ,
- X is  $-\text{C}(\text{R}^4)_2\text{]}_n\text{CONR}^3\text{C}(\text{R}^4)_2\text{]}_n-$ ,  $-\text{C}(\text{R}^4)_2\text{]}_n\text{NR}^3\text{CO}\text{C}(\text{R}^4)_2\text{]}_n-$ ,  $-\text{C}(\text{R}^4)_2\text{]}_n\text{NR}^3\text{C}(\text{R}^4)_2\text{]}_n-$ ,  $-\text{C}(\text{R}^4)_2\text{]}_n\text{O}\text{C}(\text{R}^4)_2\text{]}_n-$ ,  $-\text{C}(\text{R}^4)_2\text{]}_n\text{CO}\text{C}(\text{R}^4)_2\text{]}_n-$  or  $-\text{C}(\text{R}^4)_2\text{]}_n\text{COO}\text{C}(\text{R}^4)_2\text{]}_n-$ ,
- Y is alkylene, cycloalkylene, Het-diyl or Ar-diyl,
- T is a monocyclic or bicyclic, saturated or unsaturated carbocyclic or heterocyclic ring having from 0 to 4 N, O and/or S atoms which is monosubstituted or disubstituted by  $=\text{O}$ ,  $=\text{S}$ ,  $=\text{NR}^3$ ,  $=\text{N-CN}$ ,  $=\text{N-NO}_2$ ,  $=\text{NOR}^3$ ,  $=\text{NCOR}^3$ ,  $=\text{NCOOR}^3$  or  $=\text{NOCOR}^3$  and may furthermore be monosubstituted, disubstituted or trisubstituted by  $\text{R}^3$ , Hal, A,  $-\text{C}(\text{R}^4)_2\text{]}_n\text{-Ar}$ ,  $-\text{C}(\text{R}^4)_2\text{]}_n\text{-Het}$ ,  $-\text{C}(\text{R}^4)_2\text{]}_n\text{-cycloalkyl}$ ,  $\text{OR}^3$ ,  $\text{N}(\text{R}^3)_2$ ,  $\text{NO}_2$ ,  $\text{CN}$ ,  $\text{COOR}^3$ ,  $\text{CON}(\text{R}^3)_2$ ,  $\text{NR}^3\text{COA}$ ,  $\text{NR}^3\text{CON}(\text{R}^3)_2$ ,  $\text{NR}^3\text{SO}_2\text{A}$ ,  $\text{COR}^3$ ,  $\text{SO}_2\text{NR}^3$  and/or  $\text{S}(\text{O})_n\text{A}$ ,
- A is unbranched or branched alkyl having 1-10 carbon atoms in which one or two  $\text{CH}_2$  groups may be replaced by O or S atoms and/or by  $-\text{CH}=\text{CH}-$  groups and/or in addition 1-7 H atoms may be replaced by F,
- Ar is phenyl, naphthyl or biphenyl, each of which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, A,  $\text{OR}^3$ ,  $\text{N}(\text{R}^3)_2$ ,  $\text{NO}_2$ ,  $\text{CN}$ ,  $\text{COOR}^3$ ,  $\text{CON}(\text{R}^3)_2$ ,  $\text{NR}^3\text{COA}$ ,  $\text{NR}^3\text{CON}(\text{R}^3)_2$ ,  $\text{NR}^3\text{SO}_2\text{A}$ ,  $\text{COR}^3$ ,  $\text{SO}_2\text{N}(\text{R}^3)_2$ ,  $\text{S}(\text{O})_n\text{A}$ ,  $-\text{C}(\text{R}^4)_2\text{]}_n\text{-COOR}^3$  or  $-\text{O}\text{C}(\text{R}^4)_2\text{]}_n\text{-COOR}^3$ ,
- Ar' is phenyl, naphthyl or biphenyl, each of which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, A,  $\text{OR}^4$ ,  $\text{N}(\text{R}^4)_2$ ,  $\text{NO}_2$ ,  $\text{CN}$ ,  $\text{COOR}^4$ ,  $\text{CON}(\text{R}^4)_2$ ,  $\text{NR}^4\text{COA}$ ,  $\text{NR}^4\text{CON}(\text{R}^4)_2$ ,  $\text{NR}^4\text{SO}_2\text{A}$ ,  $\text{COR}^4$ ,  $\text{SO}_2\text{N}(\text{R}^4)_2$ ,  $\text{S}(\text{O})_n\text{A}$ ,  $-\text{C}(\text{R}^4)_2\text{]}_n\text{-COOR}^4$  or  $-\text{O}\text{C}(\text{R}^4)_2\text{]}_n\text{-COOR}^4$ ,
- Het is a monocyclic or bicyclic, saturated, unsaturated or aromatic heterocyclic ring having from 1 to 4 N, O and/or S atoms which may be unsubstituted or monosubstituted, disubstituted or

trisubstituted by Hal, A,  $-\text{[C(R}^4\text{)]}_n\text{-Ar}$ ,  $-\text{[C(R}^4\text{)]}_n\text{-Het'}$ ,  $-\text{[C(R}^4\text{)]}_n\text{-cycloalkyl}$ ,  $\text{OR}^3$ ,  $\text{N(R}^3\text{)}_2$ ,  $\text{NR}^3\text{CON(R}^3\text{)}_2$ ,  $\text{NO}_2$ ,  $\text{CN}$ ,  $-\text{[C(R}^4\text{)]}_n\text{-COOR}^3$ ,  $-\text{[C(R}^4\text{)]}_n\text{-CON(R}^3\text{)}_2$ ,  $\text{NR}^3\text{COA}$ ,  $\text{NR}^3\text{SO}_2\text{A}$ ,  $\text{COR}^3$ ,  $\text{SO}_2\text{NR}^3$ ,  $\text{S(O)}_m\text{A}$  and/or carbonyl oxygen,

Het' is a monocyclic or bicyclic, saturated, unsaturated or aromatic heterocyclic ring having from 1 to 4 N, O and/or S atoms which may be unsubstituted or monosubstituted or disubstituted by carbonyl oxygen,  $=\text{S}$ ,  $=\text{N(R}^4\text{)}_2$ , Hal, A,  $\text{OR}^4$ ,  $\text{N(R}^4\text{)}_2$ ,  $\text{NO}_2$ ,  $\text{CN}$ ,  $\text{COOR}^4$ ,  $\text{CON(R}^4\text{)}_2$ ,  $\text{NR}^4\text{COA}$ ,  $\text{NR}^4\text{CON(R}^4\text{)}_2$ ,  $\text{NR}^4\text{SO}_2\text{A}$ ,  $\text{COR}^4$ ,  $\text{SO}_2\text{NR}^4$  and/or  $\text{S(O)}_n\text{A}$ ,

Hal is F, Cl, Br or I,

n is 0, 1 or 2,

o is 1, 2 or 3,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

2. (Original) Compounds according to Claim 1, in which

D is a monocyclic or bicyclic, aromatic carbocyclic or heterocyclic ring having from 0 to 4 N, O and/or S atoms which is unsubstituted or monosubstituted or disubstituted by Hal, and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

3. (Currently Amended) Compounds according to Claim 1 ~~or 2~~, in which

D is phenyl, pyridyl, thienyl, furyl or imidazolyl, each of which is monosubstituted or disubstituted by Hal, and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

4. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-3~~,

in which

$R^1, R^2$  are each, independently of one another, H, =O,  $\text{COOR}^3$ , OH, OA,  $\text{NH}_2$ ,  
alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,  $\text{N}_3$ , ethynyl, vinyl,  
allyloxy,  $\text{NHCOA}$ ,  $\text{NHSO}_2\text{A}$ ,  $\text{OCH}_2\text{COOA}$  or  $\text{OCH}_2\text{COOH}$ ,  
and pharmaceutically usable derivatives, solvates, salts and stereoisomers  
thereof, including mixtures thereof in all ratios.

5. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-4~~,

in which

G is  $(\text{CH}_2)_n$ ,  $(\text{CH}_2)_n\text{NH}-$ ,  $-\text{CH}=\text{CH}-$  or  $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$ ,  
and pharmaceutically usable derivatives, solvates, salts and stereoisomers  
thereof, including mixtures thereof in all ratios.

6. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-5~~,

in which

X is  $-\text{C}(\text{R}^4)_2]_n\text{CONR}^3[\text{C}(\text{R}^4)_2]_n-$ ,  
and pharmaceutically usable derivatives, solvates, salts and stereoisomers  
thereof, including mixtures thereof in all ratios.

7. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-6~~,

in which

X is  $-\text{CONH}-$  or  $-\text{CON}(\text{CH}_2\text{COOA})-$ ,  
and pharmaceutically usable derivatives, solvates, salts and stereoisomers  
thereof, including mixtures thereof in all ratios.

8. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-7~~,

in which

Y is cycloalkylene, Het-diyl or Ar-diyl,  
and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

9. (Currently Amended) Compounds according to claim 1 ~~Claims 1-8~~,  
in which

Y is pyridinediyl, piperidinediyl, cyclohexylene, or phenylene which is unsubstituted or monosubstituted or disubstituted by A, OA, Cl, F, COOCH<sub>3</sub>, COOH, phenoxy or aminocarbonyl,  
and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

10. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-9~~,

in which

T is a monocyclic, saturated or unsaturated heterocyclic ring having 1 to 2 N and/or O atoms which is monosubstituted or disubstituted by =O, =S or =NH and may be monosubstituted or disubstituted by Hal, A and/or OA,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

11. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-10~~,

in which

T is piperidin-1-yl, pyrrolidin-1-yl, pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl, imidazolidinyl, thiazolyl or 1,4-oxazepanyl, each of which is monosubstituted or disubstituted by =O or =NH and where the radicals may also be monosubstituted or disubstituted by Hal, A and/or OA,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

12. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-11~~,

in which

Ar is phenyl which is unsubstituted or monosubstituted or disubstituted by Hal, A, OA, SO<sub>2</sub>A, COOR<sup>2</sup>, SO<sub>2</sub>NH<sub>2</sub>, CN, COOA, COOH or phenoxy,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

13. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-12~~,

in which

D is a monocyclic or bicyclic, aromatic carbocyclic or heterocyclic ring having from 0 to 4 N, O and/or S atoms which is

unsubstituted or monosubstituted or disubstituted by Hal,

R<sup>1</sup>, R<sup>2</sup> are each, independently of one another, H, =O, COOR<sup>3</sup>, OH, OA, NH<sub>2</sub>, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N<sub>3</sub>, ethynyl, vinyl, allyloxy, NHCOA, NHSO<sub>2</sub>A, OCH<sub>2</sub>COOA or OCH<sub>2</sub>COOH,

R<sup>1</sup> and R<sup>2</sup> together are alternatively a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R<sup>3</sup> is H, A, phenyl, benzyl or [C(R<sup>4</sup>)<sub>2</sub>]<sub>n</sub>COOA,

R<sup>4</sup> is H or A,

W is N, CR<sup>3</sup> or an sp<sup>2</sup>-hybridised carbon atom,

E together with W is a 3- to 7-membered saturated carbocyclic or heterocyclic ring having from 0 to 3 N, from 0 to 2 O and/or from 0 to 2 S atoms,  
which may contain a double bond,

G	is $(\text{CH}_2)_n$ , $(\text{CH}_2)_n\text{NH}$ -, $-\text{CH}=\text{CH}-$ or $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$ ,
X	is $-\text{[C(R}^4\text{)]}_n\text{CONR}^3\text{[C(R}^4\text{)]}_n-$ ,
Y	is cycloalkylene, Het-diyl or Ar-diyl,
Ar	is phenyl which is unsubstituted or monosubstituted or disubstituted by Hal, A, OA, $\text{SO}_2\text{A}$ , $\text{COOR}^2$ , $\text{SO}_2\text{NH}_2$ , CN, COOA, COOH or phenoxy,
T	is a monocyclic, saturated or unsaturated heterocyclic ring having 1 to 2 N and/or O atoms which is monosubstituted or disubstituted by =O, =S or =NH and may be monosubstituted or disubstituted by Hal, A and/or OA,
A	is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms may be replaced by F,
Hal	is F, Cl, Br or I,
n	is 0, 1 or 2,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

14. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-13~~,

in which

D	is phenyl, pyridyl, thienyl, furyl or imidazolyl, each of which is monosubstituted or disubstituted by Hal,
$\text{R}^1$ , $\text{R}^2$	are each, independently of one another, H, =O, $\text{COOR}^3$ , OH, OA, $\text{NH}_2$ , alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, $\text{N}_3$ , ethynyl, vinyl, allyloxy, $\text{NHCOA}$ , $\text{NHSO}_2\text{A}$ , $\text{OCH}_2\text{COOA}$ or $\text{OCH}_2\text{COOH}$ ,
$\text{R}^1$ and $\text{R}^2$	together are alternatively a spirocyclically bonded 3- to 6-membered carbocyclic ring,
$\text{R}^3$	is H, A or $\text{CH}_2\text{COOA}$ ,
$\text{R}^4$	is H or A,
W	is N, $\text{CR}^3$ or an $\text{sp}^2$ -hybridised carbon atom,

E together with W is a 3- to 7-membered saturated carbocyclic or heterocyclic ring having from 0 to 3 N, from 0 to 2 O and/or from 0 to 2 S atoms,  
which may contain a double bond,

G is  $(CH_2)_n$ ,  $(CH_2)_nNH-$ ,  $-CH=CH-$  or  $-CH=CH-CH=CH-$ ,

X is  $-CONH-$  or  $-CON(CH_2COOA)-$ ,

Y is pyridinediyl, piperidinediyl, cyclohexylene, or phenylene which is unsubstituted or monosubstituted or disubstituted by A, OA, Cl, F,  $COOCH_3$ ,  $COOH$ , phenoxy or aminocarbonyl,

T is piperidin-1-yl, pyrrolidin-1-yl, pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl, imidazolidinyl, thiazolyl or 1,4-oxazepanyl, each of which is monosubstituted or disubstituted by  $=O$  or  $=NH$  and where the radicals may also be monosubstituted or disubstituted by Hal, A and/or OA,

A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms may be replaced by F,

Hal is F, Cl, Br or I,

n is 0, 1 or 2,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

15. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-14~~,


in which

D is phenyl, pyridyl or thienyl, each of which is monosubstituted or disubstituted by Hal,


$R^1$  is H,  $=O$ ,  $COOR^3$ , OH, OA,  $NH_2$ , alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,  $N_3$ , ethynyl, vinyl, allyloxy,  $-OCOR^3$ ,  $NHCOA$  or  $NHSO_2A$ ,

$R^2$  is H,  $=O$ , OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon



atoms,  
 $R^1$  and  $R^2$  together are alternatively a spirocyclically bonded 3- to 6-membered carbocyclic ring,  
 $R^3$  is H or A,  
 $R^4$  is H or A,  
 is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl, thiazolidine-3,4-diyl, 2,5-dihydro-1*H*-pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or azetidine-1,2-diyl,  
G is  $(CH_2)_n$  or  $(CH_2)_nNH-$ ,  
X is CONH,  
Y is 1,3- or 1,4-phenylene which is unsubstituted or mono-substituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,  
T is piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo[2.2.2]octan-2-yl, each of which is monosubstituted or disubstituted by carbonyl oxygen,  
A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms may be replaced by F,  
Hal is F, Cl, Br or I,  
n is 0, 1 or 2;  
and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

16. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-15~~,  
in which  
D is phenyl, pyridyl or thienyl, each of which is monosubstituted

	or disubstituted by Hal,
R <sup>1</sup>	is H, =O, COOR <sup>3</sup> , OH, OA, NH <sub>2</sub> , alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N <sub>3</sub> , ethynyl, vinyl, allyloxy, -OCOR <sup>3</sup> , NHCOA or NHSO <sub>2</sub> A,
R <sup>2</sup>	is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,
R <sup>1</sup> and R <sup>2</sup>	together are alternatively a spirocyclically bonded 3- to 6-membered carbocyclic ring,
R <sup>3</sup>	is H or A,
R <sup>4</sup>	is H or A,
	is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl, thiazolidine-3,4-diyl, 2,5-dihydro-1 <i>H</i> -pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or azetidine-1,2-diyl,
G	is (CH <sub>2</sub> ) <sub>n</sub> or (CH <sub>2</sub> ) <sub>n</sub> NH-,
X	is CONH,
Y	is 1,3- or 1,4-phenylene which is unsubstituted or mono-substituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,
T	is morpholin-4-yl which is monosubstituted or disubstituted by carbonyl oxygen,
A	is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms may be replaced by F,
Hal	is F, Cl, Br or I,
n	is 0, 1 or 2;

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

17. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-16~~,

in which

X is  $-[C(R^4)_2]_nCONR^3[C(R^4)_2]_n-$  or  $-[C(R^4)_2]_nCO[C(R^4)_2]_n-$ ,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

18. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-17~~,

in which

X is CONH or COCH<sub>2</sub>,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

19. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-18~~,

in which

D is phenyl, pyridyl or thienyl, each of which is monosubstituted or disubstituted by Hal,


R<sup>1</sup> is H, =O, COOR<sup>3</sup>, OH, OA, NH<sub>2</sub>, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N<sub>3</sub>, ethynyl, vinyl, allyloxy, -OCOR<sup>3</sup>, NHCOA or NHSO<sub>2</sub>A,

R<sup>2</sup> is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R<sup>1</sup> and R<sup>2</sup> together are alternatively a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R<sup>3</sup> is H or A,

R<sup>4</sup> is H or A,



is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or

3,5-diyl, thiazolidine-3,4-diyl, 2,5-dihydro-1H-pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or azetidine-1,2-diyl,


G	is $(\text{CH}_2)_n$ or $(\text{CH}_2)_n\text{NH}-$ ,
X	is CONH or $\text{COCH}_2$ ,
Y	is 1,3- or 1,4-phenylene which is unsubstituted or mono-substituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,
T	is morpholin-4-yl which is monosubstituted or disubstituted by carbonyl oxygen,
A	is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms may be replaced by F,
Hal	is F, Cl, Br or I,
n	is 0, 1 or 2,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

20. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-19~~,

in which

D	is phenyl, pyridyl or thienyl, each of which is monosubstituted or disubstituted by Hal,
R <sup>1</sup>	is H, =O, $\text{COOR}^3$ , OH, OA, $\text{NH}_2$ , alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, $\text{N}_3$ , ethynyl, vinyl, allyloxy, $-\text{OCOR}^3$ , $\text{NHCOA}$ , $\text{NHSO}_2\text{A}$ , $\text{H}-\text{C}\equiv\text{C}-\text{CH}_2-$ , $\text{CH}_3-\text{C}\equiv\text{C}-\text{CH}_2-\text{O}-$ , $-\text{O}-\text{CH}_2-\text{CH}(\text{OH})-\text{CH}_2\text{OH}$ , $-\text{O}-\text{CH}_2-\text{CH}(\text{OH})-\text{CH}_2\text{NH}_2$ or $-\text{O}-\text{CH}_2-\text{CH}(\text{OH})-\text{CH}_2\text{Het}'$ ,
R <sup>2</sup>	is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,
R <sup>1</sup> and R <sup>2</sup>	together are alternatively a spirocyclically bonded 3- to 6-membered carbocyclic ring,
R <sup>3</sup>	is H or A,
R <sup>4</sup>	is H or A,




- is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl, thiazolidine-3,4-diyl, 2,5-dihydro-1*H*-pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or azetidine-1,2-diyl,
- G is (CH<sub>2</sub>)<sub>n</sub> or (CH<sub>2</sub>)<sub>n</sub>NH-,
- X is CONH or COCH<sub>2</sub>,
- Y is 1,3- or 1,4-phenylene which is unsubstituted or mono-substituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,
- T is morpholin-4-yl which is monosubstituted or disubstituted by carbonyl oxygen,
- Het' is a saturated 3-6-membered heterocyclic ring having from 1 to 3 N and/or O atoms, which may be unsubstituted or monosubstituted or disubstituted by carbonyl oxygen, Hal, A, OH, NH<sub>2</sub>, NO<sub>2</sub>, CN, COOA or CONH<sub>2</sub>,
- A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms may be replaced by F,
- Hal is F, Cl, Br or I,
- n is 0, 1 or 2,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

21. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-20~~,

in which

- D is phenyl, pyridyl or thienyl, each of which is monosubstituted or disubstituted by Hal,
- R<sup>1</sup> is ethynyl, vinyl, allyloxy, CH<sub>3</sub>-C≡C-CH<sub>2</sub>-O-,  
-O-CH<sub>2</sub>-CH(OH)-CH<sub>2</sub>OH, -O-CH<sub>2</sub>-CH(OH)-CH<sub>2</sub>NH<sub>2</sub> or  
-O-CH<sub>2</sub>-CH(OH)-CH<sub>2</sub>Het',

R <sup>2</sup>	is H or OH,
R <sup>1</sup> and R <sup>2</sup>	together are alternatively a spirocyclically bonded 3- to 6-membered carbocyclic ring,
R <sup>3</sup>	is H or A,
R <sup>4</sup>	is H or A,
	is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl, thiazolidine-3,4-diyl, 2,5-dihydro-1 <i>H</i> -pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or azetidine-1,2-diyl,
G	is (CH <sub>2</sub> ) <sub>n</sub> or (CH <sub>2</sub> ) <sub>n</sub> NH-,
X	is CONH, CO, COO or COCH <sub>2</sub> ,
Y	is 1,3- or 1,4-phenylene which is unsubstituted or mono-substituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,
T	is piperidin-1-yl, pyrrolidin-1-yl, 1 <i>H</i> -pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2 <i>H</i> -pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo[2.2.2]octan-2-yl, each of which is monosubstituted or disubstituted by carbonyl oxygen or OA,
Het'	is a saturated 3-6-membered heterocyclic ring having from 1 to 3 N and/or O atoms, which may be unsubstituted or monosubstituted or disubstituted by carbonyl oxygen, Hal, A, OH, NH <sub>2</sub> , NO <sub>2</sub> , CN, COOA or CONH <sub>2</sub> ,
A	is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms may be replaced by F,
Hal	is F, Cl, Br or I,
n	is 0, 1 or 2,
and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.	

22. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-21~~,

in which

D is phenyl, pyridyl, thienyl, furyl or imidazolyl, each of which is monosubstituted or disubstituted by Hal,


R<sup>1</sup> is H, =O, COOR<sup>3</sup>, OH, OA, NH<sub>2</sub>, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N<sub>3</sub>, ethynyl, vinyl, allyloxy, NHCOA, NHSO<sub>2</sub>A, OCH<sub>2</sub>COOA or OCH<sub>2</sub>COOH,

R<sup>2</sup> is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R<sup>1</sup> and R<sup>2</sup> together are alternatively a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R<sup>3</sup> is H or A,

R<sup>4</sup> is H or A,



is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl, thiazolidine-3,4-diyl, 2,5-dihydro-1*H*-pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or azetidine-1,2-diyl,

G is (CH<sub>2</sub>)<sub>n</sub>, (CH<sub>2</sub>)<sub>n</sub>NH-, -CH=CH- or -CH=CH-CH=CH-,

X is CONH, COCH<sub>2</sub> or -CON(CH<sub>2</sub>COOA)-,

Y is pyridinediyl, piperidinediyl, cyclohexylene, or phenylene which is unsubstituted or monosubstituted or disubstituted by A, OA, Cl, F, COOCH<sub>3</sub>, COOH, phenoxy or aminocarbonyl,

T is morpholin-4-yl which is monosubstituted or disubstituted by carbonyl oxygen,

A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms may be replaced by F,

Hal is F, Cl, Br or I,

n is 0, 1 or 2,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers

thereof, including mixtures thereof in all ratios.

23. (Original) Compounds according to Claim 1, selected from the group consisting of

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-trifluoromethyl-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-piperidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-2,5-dihydropyrrole-1,2-dicarboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(R)-1-(5-chlorothiophene-2-carbonyl)pyrrolidine-2-carboxamide,

N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-(R)-1-(5-chlorothiophene-2-carbonyl)pyrrolidine-2-carboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-oxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-oxazolidine-3,4-dicarboxamide,



3-N-[(4-chlorophenyl)]-4-N-{[4-(3-oxomorpholin-4-yl)phenyl]}}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,  
 3-N-[(4-chlorophenyl)]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,  
 3-N-[(4-chlorophenyl)]-4-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}}-(R)-oxazolidine-3,4-dicarboxamide,  
 3-N-[(4-chlorophenyl)]-4-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,  
 3-N-[(4-chlorophenyl)]-4-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,  
 3-N-[(4-chlorophenyl)]-4-N-{[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]}}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,  
 3-N-[(4-chlorophenyl)]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}}-(4R,5R)-5-methyloxazolidine-3,4-dicarboxamide,  
 3-N-[(4-chlorophenyl)]-4-N-{[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]}}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,  
 3-N-[(4-chlorophenyl)]-4-N-{[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]}}-(R)-oxazolidine-3,4-dicarboxamide,  
 3-N-[(4-chlorophenyl)]-4-N-{[3-chloro-4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}}-(R)-oxazolidine-3,4-dicarboxamide,  
 3-N-[(4-chlorophenyl)]-4-N-{[4-(3-oxomorpholin-4-yl)phenyl]}}-(S)-thiazolidine-3,4-dicarboxamide,  
 3-N-[(4-chlorophenyl)]-4-N-{[4-(3-oxomorpholin-4-yl)phenyl]}}-(S)-1,1-dioxo-1 $\lambda^6$ -thiazolidine-3,4-dicarboxamide,  
 3-N-[(4-chlorophenyl)]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}}-(S)-thiazolidine-3,4-dicarboxamide,  
 3-N-[(4-chlorophenyl)]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}}-(S)-1,1-dioxo-1 $\lambda^6$ -thiazolidine-3,4-dicarboxamide,  
 3-N-[(4-chlorophenyl)]-4-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}}-(R)-thiazolidine-3,4-dicarboxamide,  
 N-[4-(3-oxomorpholin-4-yl)phenyl]-3-(5-chlorothiophene-2-

carbonyl)oxazolidine-5-carboxamide,

N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-(5-chlorothiophene-2-carbonyl)oxazolidine-5-carboxamide,

N-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-3-(5-chlorothiophene-2-carbonyl)oxazolidine-5-carboxamide,

1-N-[(5-chloropyridin-2-yl)]-2-N-{{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}}-(2*R*,4*R*)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(5-chloropyridin-2-yl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}}-(2*R*,4*R*)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(5-chloropyridin-2-yl)]-2-N-{{[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]}}-(2*R*,4*R*)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(5-chloropyridin-2-yl)]-2-N-{{[3-fluoro-4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}}-(2*R*,4*R*)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(5-chloropyridin-2-yl)]-2-N-{{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}}-(*R*)-4,4-dimethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(5-chloropyridin-2-yl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}}-(*R*)-4,4-dimethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}}-(*R*)-4,4-dimethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}}-(2*R*,4*R*)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}}-(2*R*,4*R*)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}}-(2*R*,4*R*)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}}-(2*R*,4*R*)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(2-oxopyrazin-1-yl)phenyl]}}-(2*R*,4*R*)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[3-fluoro-4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}}-(2*R*,4*R*)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[3-fluoro-4-(3-oxomorpholin-4-yl)-phenyl]}}-(2R,3R)-3-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[3-fluoro-4-(3-oxomorpholin-4-yl)-phenyl]}}-(2R,3S)-3-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}}-(2R,4S)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}}-(2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}}-3,4-dihydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}}-(2R,4S)-4-azidopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}}-(2R,4S)-4-aminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}}-(2R,4R)-4-azidopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}}-(2R,4R)-4-aminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}}-(2R,4S)-4-acetaminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}}-(2R,4R)-4-acetaminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}}-(2R,4S)-4-methylsulfonylaminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}}-(2R,4R)-4-methylsulfonylaminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[4-(3-oxomorpholin-4-yl)phenyl]}}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}}-(2R,4R)-4-propoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}}-(2R,4R)-4-allyloxypyrrolidine-1,2-dicarboxamide,

(3R,5R)-1-(4-chlorophenylcarbamoyl)-5-[4-(3-oxomorpholin-4-yl)-phenylcarbamoyl]pyrrolidin-3-yl isobutyrate,

(3R,5R)-1-(4-chlorophenylcarbamoyl)-5-[4-(3-oxomorpholin-4-yl)-phenylcarbamoyl]pyrrolidin-3-yl propionate,

(3R,5R)-1-(4-chlorophenylcarbamoyl)-5-[4-(3-oxomorpholin-4-yl)-phenylcarbamoyl]pyrrolidin-3-yl acetate,

4-N-[(4-chlorophenyl)]-5-N-{[4-(3-oxomorpholin-4-yl)phenyl]}}-1,3-dioxolane-4,5-dicarboxamide,

4-N-[(4-chlorophenyl)]-5-N-{[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]}}-1,3-dioxolane-4,5-dicarboxamide,

4-N-[(4-chlorophenyl)]-5-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}}-1,3-dioxolane-4,5-dicarboxamide,

4-N-[(4-chlorophenyl)]-5-N-{[4-(3-oxomorpholin-4-yl)phenyl]}}-1,3-dioxolane-2,2-dimethyl-4,5-dicarboxamide,

4-N-[(4-chlorophenyl)]-5-N-{[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]}}-1,3-dioxolane-2,2-dimethyl-4,5-dicarboxamide,

4-N-[(4-chlorophenyl)]-5-N-{[4-(2-oxo-1*H*-pyridin-1-yl)phenyl]}}-1,3-dioxolane-2,2-dimethyl-4,5-dicarboxamide,

1-N-[4-chlorophenyl]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}}-1-BOC-piperazine-1,2-dicarboxamide,

1-N-[4-chlorophenyl]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}}-piperazine-1,2-dicarboxamide,

1-N-[4-chlorophenyl]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}}-1,3-oxazinane-3,4-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}}-(2R,4S)-4-ethynyl-4-hydroxypyrrolidine-1,2-dicarboxamide,

6-N-[(4-chlorophenyl)]-7-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-4-oxa-6-azaspiro[2.4]heptane-6,7-dicarboxamide,

1-N-[(6-chloropyridin-3-yl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2*R*,4*R*)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(6-chloropyridin-3-yl)]-2-N-{[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]}-(2*R*,4*R*)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]}-(2*R*,4*S*)-4-acetaminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2*R*,4*S*)-4-butylsulfonylaminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(*R*)-4-oxopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]}-(2*R*,4*S*)-4-aminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]}-(*S*)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)-phenyl]}-(2*R*,4*R*)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2*R*,4*R*)-1-[2-(4-chlorophenyl)-acetyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2*R*,4*R*)-1-(4-chlorobenzoyl)-4-hydroxypyrrolidine-2-carboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]}-(2*R*,4*R*)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2*R*,4*R*)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)-phenyl]}-(2*R*,4*R*)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]}-(2*R*,4*R*)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-(2-methylpropanoylamino)pyrrolidine-1,2-dicarboxamide,  
N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-(1-*H*-indol-3-yl-methanoyl)-4-hydroxypyrrolidine-2-carboxamide,  
N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-(1-*H*-indol-6-yl-methanoyl)-4-hydroxypyrrolidine-2-carboxamide,  
1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,  
1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-1*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,  
1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)-phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,  
1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-1*H*-pyridin-1-yl)phenyl]}-(2R,4S)-4-ethynyl-4-hydroxypyrrolidine-1,2-dicarboxamide,  
1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]}-(2R,4S)-4-ethynyl-4-hydroxypyrrolidine-1,2-dicarboxamide,  
1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-4,4-difluoro-(*R*)-pyrrolidine-1,2-dicarboxamide,  
1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(2-oxo-2*H*-pyridin-1-yl)-phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,  
1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(2-oxo-2*H*-pyridin-1-yl)-phenyl]}-(*R*)-pyrrolidine-1,2-dicarboxamide,  
1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(2-oxo-2*H*-pyridin-1-yl)-phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,  
2-N-[(4-chlorophenyl)]-1-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(*R*)-pyrrolidine-1,2-dicarboxamide,  
2-N-[(4-chlorophenyl)]-1-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(*S*)-pyrrolidine-1,2-dicarboxamide,  
1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-3-methoxy-2*H*-pyridin-1-yl)-phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-3-methoxy-2*H*-pyridin-1-yl)-phenyl]}-(*R*)-pyrrolidine-1,2-dicarboxamide,

N-(4-chlorophenyl)-(*R*)-1-{2-[4-(3-oxomorpholin-4-yl)phenyl]-acetyl}pyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(*S*)-1-{2-[4-(3-oxomorpholin-4-yl)phenyl]-acetyl}pyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(*2R,4R*)-1-{2-[4-(3-oxomorpholin-4-yl)phenyl]-acetyl}-4-methoxypyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(*2R,4S*)-1-{2-[4-(3-oxomorpholin-4-yl)phenyl]-acetyl}-4-methoxypyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(*2S,4R*)-1-{2-[4-(3-oxomorpholin-4-yl)-phenyl]acetyl}-4-methoxypyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(*S*)-1-{2-[4-(2-oxo-1*H*-pyridin-1-yl)phenyl]-acetyl}pyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(*S*)-1-{2-[4-(2-oxopyrrolidin-1-yl)phenyl]-acetyl}pyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(*R*)-1-{2-[4-(2-oxopyrrolidin-1-yl)phenyl]-acetyl}pyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(*R*)-1-[4-(2-oxopiperidin-1-yl)benzoyl]pyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(*R*)-1-[4-(2-oxopiperidin-1-yl)phenyloxy-carbonyl]pyrrolidine-2-carboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]}-(*2R,4R*)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)-phenyl]}-(*2R,4R*)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(*2R,4R*)-4-(prop-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(*2R,4R*)-4-(but-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{4-(3-oxomorpholin-4-yl)phenyl}}-(2R,4R)-4-(2,3-dihydroxypropoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{4-(3-oxomorpholin-4-yl)phenyl}}-(2R,4R)-4-(2-hydroxy-3-pyrrolidin-1-ylpropoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{4-(3-oxomorpholin-4-yl)phenyl}}-(2R,4R)-4-(2-oxooxazolidin-5-ylmethoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{4-(3-oxomorpholin-4-yl)phenyl}}-(2R,4R)-4-(3-amino-2-hydroxypropoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{4-(2-oxo-1*H*-pyrazin-1-yl)phenyl}}-(R)-2,5-dihydropyrrole-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{4-(2-oxo-1*H*-pyridin-1-yl)phenyl}}-(R)-2,5-dihydropyrrole-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{3-fluoro-4-(3-oxomorpholin-4-yl)phenyl}}-(R)-2,5-dihydropyrrole-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{2-fluoro-4-(3-oxomorpholin-4-yl)phenyl}}-(R)-2,5-dihydropyrrole-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{4-(3-oxomorpholin-4-yl)phenyl}}-(2S,3S)-3-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{4-(3-oxomorpholin-4-yl)phenyl}}-(2S,4S)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{2-methoxycarbonyl-4-(3-oxomorpholin-4-yl)phenyl}}-(2R,4R)-3-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{2-carboxy-4-(3-oxomorpholin-4-yl)phenyl}}-(2R,4R)-3-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{4-(3-oxomorpholin-4-yl)phenyl}}-(2R,3S,4R)-3,4-dihydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{2-fluoro-4-(3-oxomorpholin-4-yl)phenyl}}-(2R,4R)-4-allyloxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{2-fluoro-4-(3-oxomorpholin-4-yl)phenyl}}-(2R,4R)-4-(prop-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,



1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)-phenyl]}-(2R,4S)-4-(prop-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(methoxycarbonylmethoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(carboxymethoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-bromophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)-phenyl]}-(2R,4R)-4-methoxypyrrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)-phenyl]}-(2R,4R)-4-(2,3-dihydroxypropoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{N-methoxycarbonylmethyl-N'-[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)cyclohexan-1-yl]}-(2R,4R)-4-hydroxypyrrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-iminopyrrolidin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrrolidine-1,2-dicarboxamide, ESI 442;

1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(2-iminopyrrolidin-1-yl)-phenyl]}-(2R,4R)-4-hydroxypyrrrolidine-1,2-dicarboxamide, ESI 456;

1-N-[(4-chlorophenyl)]-2-N-[4-{2-[(E)-cyanimino]imidazolidin-1-yl)-phenyl]}-(2R,4R)-4-hydroxypyrrrolidine-1,2-dicarboxamide, ESI 468;

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-imino-5-methylthiazol-3-yl)-phenyl]}-(2R,4R)-4-hydroxypyrrrolidine-1,2-dicarboxamide, ESI 473;

1-N-[(4-chlorophenyl)]-2-N-{[2-aminocarbonyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrrolidine-1,2-dicarboxamide, ESI 502;

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxy-2-methylpyrrolidine-1,2-dicarboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorothiophen-2-yl)acryloyl]-4-hydroxypyrrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-thiophen-3-ylacryloyl]-4-hydroxypyrrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(2E,4E)-5-phenylpenta-2,4-dienyloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-methylfuran-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-thiophen-2-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorothiophen-2-yl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorothiophen-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chlorophenyl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-dichlorophenyl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chlorophenyl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-dichlorophenyl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1*H*-imidazol-4-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorothiophen-2-yl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorofuran-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorofuran-2-yl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chlorophenyl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-dichlorophenyl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorofuran-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorothiophen-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chlorophenyl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-dichlorophenyl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorofuran-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorofuran-2-yl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chlorophenyl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-dichlorophenyl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chlorophenyl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-dichlorophenyl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorofuran-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorothiophen-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1*H*-imidazol-4-ylacryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1*H*-imidazol-4-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1*H*-imidazol-4-ylacryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1*H*-imidazol-4-ylacryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-ylacryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-ylacryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-ylacryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-ylacryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-4-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-4-ylacryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1*H*-imidazol-4-ylacryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-bromothiophen-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-bromothiophen-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-bromothiophen-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-bromothiophen-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(R)-1-[4-(2-oxopiperidin-1-yl)benzoyl]pyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(S)-1-[4-(2-oxopiperidin-1-yl)benzoyl]pyrrolidine-2-carboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{4-(5-oxo-1,4-oxazepan-4-yl)phenyl}}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{4-(5-oxo-1,4-oxazepan-4-yl)phenyl}}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{4-((S)-2-methyl-3-oxomorpholin-4-yl)phenyl}}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{4-((S)-2-methyl-3-oxomorpholin-4-yl)phenyl}}-(2R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{4-((R)-2-methyl-3-oxomorpholin-4-yl)phenyl}}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{4-((R)-2-methyl-3-oxomorpholin-4-yl)phenyl}}-(2R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{4-(3-oxomorpholin-4-yl)-2-phenoxyphenyl}}-(2R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{2-fluoro-4-((R)-2-methyl-3-oxomorpholin-4-yl)phenyl}}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-3-N-{{4-(3-oxomorpholin-4-yl)phenyl}}-piperidine-1,3-dicarboxamide,

1-N-[(4-chlorophenyl)]-3-N-{{3-methyl-4-(3-oxomorpholin-4-yl)phenyl}}-piperidine-1,3-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{4-(3-oxomorpholin-4-yl)phenyl}}-(2R,4R)-4-(2-methoxyethoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{4-(3-oxo-1,4-oxazepan-4-yl)phenyl}}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{2-methyl-4-(3-oxomorpholin-4-yl)phenyl}}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{4-(3-oxomorpholin-4-yl)phenyl}}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{{[2-(3-oxomorpholin-4-yl)phenyl]}}-  
(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

24. (Original) Pyrrolidinecarboxylic acid derivatives selected from the group consisting of

1-N-[(4-chlorophenyl)]-2-N-[(1'-methyl-[1,4']bipiperidiny-4-yl)]-  
(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[(3,4,5,6-tetrahydro-2*H*-1,4'-bipyridinyl-4-yl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[(3,4,5,6-tetrahydro-2*H*-1,4'-bipyridinyl-4-yl)]-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

N-(4-chlorophenyl)-(2R,4R)-4-hydroxy-2-(4-pyridin-4-ylpiperazine-1-carbonyl)pyrrolidine-1-carboxamide,

N-(4-chlorophenyl)-(2R,4R)-4-hydroxy-2-[4-(2-methoxyphenyl)-piperazine-1-carbonyl]pyrrolidine-1-carboxamide,

N-(4-chlorophenyl)-(2R,4R)-2-[4-(4-fluorophenyl)piperazine-1-carbonyl]-4-hydroxypyrrolidine-1-carboxamide,

N-(4-chlorophenyl)-(2R,4R)-4-hydroxy-2-[4-hydroxy-4-(4-methoxyphenyl)piperidine-1-carbonyl]pyrrolidine-1-carboxamide,

N-(4-chlorophenyl)-(2R,4R)-4-hydroxy-2-(4-pyridin-2-ylpiperazine-1-carbonyl)pyrrolidine-1-carboxamide,

N-(4-chlorophenyl)-(2R,4R)-2-[4-(4-ethylpiperazin-1-yl)piperidine-1-carbonyl]-4-hydroxypyrrolidine-1-carboxamide,

N-(4-chlorophenyl)-(2R,4R)-2-[4-(4,6-dimethylpyrimidin-2-yl)-piperazine-1-carbonyl]-4-hydroxypyrrolidine-1-carboxamide,

N-(4-chlorophenyl)-(2R,4R)-4-hydroxy-2-[4-(1-methylpiperidin-4-yl)-piperazine-1-carbonyl]pyrrolidine-1-carboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-(2-dimethylaminoethoxy)-4-morpholin-4-ylphenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[(2-ethoxy-4-morpholin-4-ylphenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[(4-morpholin-4-yl-2-propoxyphenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

25. (Original) Cyclopentanecarboxylic acid derivatives selected from the group consisting of

N-[4-(3-oxomorpholin-4-yl)phenyl]-(rac)-2-[3-(4-chlorophenyl)-ureido]cyclopentanecarboxamide,

N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-(rac)-2-[3-(4-chlorophenyl)ureido]cyclopentanecarboxamide,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

26. (Currently Amended) Process for the preparation of compounds of the formula I according to claim 1 ~~Claims 1-23~~ and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, characterised in that

a) for the preparation of compounds of the formula I in which

W is N and

G is NH,

a compound of the formula II



$R^1, R^2, E, X, Y$  and  $T$  are as defined in Claim 1,  
and  $W$  is  $N$ ,

is reacted with a compound of the formula III



D is as defined in Claim 1,

b) for the preparation of compounds of the formula I in which  
X is  $-[C(R^4)_2]_nCONR^3[C(R^4)_2]_n-$ ,


a compound of the formula IV



in which  $R^3$ ,  $n$ ,  $Y$  and  $T$  are as defined in Claim 1,

is reacted with a compound of the formula V





V


in which

L is Cl, Br, I or a free or reactively functionally modified OH group, and R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup>, D, E, G, W and n are as defined in Claim 1,

or

c) for the preparation of compounds of the formula I in which W is N,

a compound of the formula II



II

in which

R<sup>1</sup>, R<sup>2</sup>, E, X, Y and T are as defined in Claim 1, and W is N,

is reacted with a compound of the formula VI



VI

in which D and G are as defined in Claim 1, and

L is Cl, Br, I or a free or reactively functionally modified OH group,

and/or


a base or acid of the formula I is converted into one of its salts.

27. Canceled
28. Cancelled.
29. (Currently Amended) Medicament comprising at least one compound of the formula I according to claim 1 ~~one or more of Claims 1 to 23 or a compound of Claims 24 and 25~~ and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, and, if desired, excipients and/or adjuvants.
30. (Currently Amended) Medicament comprising at least one compound of the formula I according to claim 1 ~~one or more of Claims 1 to 23 or a compound of Claims 24 and 25~~ and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.
31. (Currently Amended) Use of compounds according to claim 1 ~~one or more of Claims 1 to 23 or the compounds of Claims 24 and 25~~ and/or physiologically acceptable salts, salts and solvates thereof for the preparation of a medicament for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudication intermittens, migraine, tumours, tumour diseases and/or tumour metastases.
32. (Currently Amended) Set (kit) consisting of separate packs of
  - (a) an effective amount of a compound of the formula I according to claim 1 ~~one or more of Claims 1 to 23 or a compound of Claims 24 and 25~~ and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, and

(b) an effective amount of a further medicament active ingredient.

33. (Currently Amended) Use of compounds of the formula I according to claim 1 ~~one or more of Claims 1 to 23 or of compounds of Claims 24 and 25~~ and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases, in combination with at least one further medicament active ingredient.

34. (Original) Intermediate compounds of the formula I-1




in which

D is phenyl, pyridyl, thienyl, furyl or imidazolyl, each of which is monosubstituted or disubstituted by Hal,

R<sup>1</sup> is H, OH, OA, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms or ethynyl,

R<sup>2</sup> is H, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,



is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4-

or 3,5-diyl,

G is (CH<sub>2</sub>)<sub>n</sub>, (CH<sub>2</sub>)<sub>n</sub>NH-, -CH=CH- or -CH=CH-CH=CH-,

X is COOH,

A is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,


Hal is F, Cl, Br or I,

n is 0, 1 or 2,  
and isomers and salts thereof.

35. (Original) Compounds according to Claim 34, selected from the group consisting of  
3-(4-chlorophenylcarbonyl)oxazolidine-4-carboxylic acid,  
3-(5-chlorothiophene-2-carbonyl)oxazolidine-5-carboxylic acid,  
and isomers and salts thereof.

36. (Original) Intermediate compounds selected from the group consisting of  
(2R,4S)-BOC-4-ethynyl-4-hydroxy-pyrrolidine-2-carboxylic acid,  
(2R,4R)-BOC-4-ethynyl-4-hydroxy-pyrrolidine-2-carboxylic acid,  
alkyl (2R,4S)-BOC-4-ethynyl-4-hydroxypyrrolidine-2-carboxylate,  
alkyl (2R,4R)-BOC-4-ethynyl-4-hydroxypyrrolidine-2-carboxylate,  
where alkyl has 1, 2, 3, 4, 5 or 6 carbon atoms,  
and isomers and salts thereof.

37. (Original) Intermediate compounds of the formula I-2



I-2


in which

$\text{R}^1$  is H, =O,  $\text{COOR}^3$ , OH, OA,  $\text{NH}_2$ , alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,  $\text{N}_3$ , ethynyl, vinyl, allyloxy,  $\text{NHCOA}$ ,  $\text{NHSO}_2\text{A}$ ,  $\text{OCH}_2\text{COOA}$  or  $\text{OCH}_2\text{COOH}$ ,

$\text{R}^2$  is H, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

$\text{R}^1$  and  $\text{R}^2$  together are alternatively a spirocyclically bonded 3- to 6-membered carbocyclic ring,

$\text{R}^3$  is H or A,



is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or

3,5-diyl,

X is CONH,

Y is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,

T is piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo[2.2.2]octan-2-yl, each of which is monosubstituted or disubstituted by carbonyl oxygen,


A is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

Hal is F, Cl, Br or I,

n is 0, 1 or 2,

and isomers and salts thereof.

38. (Original) Compounds according to Claim 37 of the formula I-2a




I-2a

in which

R<sup>1</sup> is H, =O, COOR<sup>3</sup>, OH, OA, NH<sub>2</sub>, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N<sub>3</sub>, ethynyl, vinyl, allyloxy, NHCOA, NHSO<sub>2</sub>A, OCH<sub>2</sub>COOA or OCH<sub>2</sub>COOH,

R<sup>2</sup> is H, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R<sup>3</sup> is H or A,



is pyrrolidine-1,2-diyl,

X is CONH,

Y is 1,3- or 1,4-phenylene which is unsubstituted or mono-substituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,

T is piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo[2.2.2]octan-2-yl, each of which is monosubstituted or disubstituted by carbonyl oxygen,

A is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

Hal is F, Cl, Br or I,

n is 0, 1 or 2,

and isomers and salts thereof.

39. (Original) Compounds according to Claim 38, selected from the group consisting of

*N*-[4-(3-oxomorpholin-4-yl)phenyl]-(*S*)-pyrrolidine-2-carboxamide,  
*N*-[4-(3-oxomorpholin-4-yl)phenyl]-(*R*)-pyrrolidine-2-carboxamide,  
*N*-[4-(3-oxomorpholin-4-yl)phenyl]-(2*R*,4*R*)-4-hydroxypyrrolidine-2-carboxamide,  
*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-hydroxypyrrolidine-2-carboxamide,  
*N*-[4-(3-oxomorpholin-4-yl)phenyl]-(*R*)-4,4-dimethoxypyrrolidine-2-carboxamide,  
*N*-[4-(3-oxomorpholin-4-yl)phenyl]-(2*R*,4*R*)-4-methoxypyrrolidine-2-carboxamide,

and isomers and salts thereof.

40. (Original) Medicament according to Claim 30, comprising 1-*N*-[(4-chlorophenyl)]-2-*N*-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2*R*,4*R*)-4-hydroxypyrrolidine-1,2-dicarboxamide and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, and aspirin.

41. (Original) Use according to Claim 33, comprising 1-N-[(4-chlorophenyl)]-2-N-{{4-(3-oxomorpholin-4-yl)phenyl}}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, in combination with aspirin.